These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25418270)

  • 21. Devitrification of amorphous celecoxib.
    Gupta P; Bansal AK
    AAPS PharmSciTech; 2005 Sep; 6(2):E223-30. PubMed ID: 16353981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. X-ray powder diffractometry of intact film coated tablets--an approach to monitor the physical form of the active pharmaceutical ingredient during processing and storage.
    Yamada H; Suryanarayanan R
    J Pharm Sci; 2007 Aug; 96(8):2029-36. PubMed ID: 17541977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability.
    Hausman DS; Cambron RT; Sakr A
    Int J Pharm; 2005 Aug; 299(1-2):19-33. PubMed ID: 15979262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example.
    Feth MP; Nagel N; Baumgartner B; Bröckelmann M; Rigal D; Otto B; Spitzenberg M; Schulz M; Becker B; Fischer F; Petzoldt C
    Eur J Pharm Sci; 2011 Jan; 42(1-2):116-29. PubMed ID: 21073949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of NIR spectroscopy to monitoring and analyzing the solid state during industrial crystallization processes.
    Févotte G; Calas J; Puel F; Hoff C
    Int J Pharm; 2004 Apr; 273(1-2):159-69. PubMed ID: 15010140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the phase transitions occurring during and after the dehydration of xylazine hydrochloride monohydrate.
    Krūkle-Bērziņa K; Actiņš A
    Int J Pharm; 2014 Jul; 469(1):40-9. PubMed ID: 24732032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical interactions between an active pharmaceutical ingredient and its counterion in a tromethamine salt under forced degradation conditions.
    Loeser E; Sutton P; Skorodinsky A; Lin M; Yowell G
    Drug Dev Ind Pharm; 2012 Mar; 38(3):357-64. PubMed ID: 22088139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of phase boundaries in anhydrate/hydrate systems.
    Krzyzaniak JF; Williams GR; Ni N
    J Pharm Sci; 2007 May; 96(5):1270-81. PubMed ID: 17455300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
    Fan Z; Zhang L
    J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging role of primary heterogeneous nucleation in pharmaceutical crystallization.
    Thakore SD; Sood A; Bansal AK
    Drug Dev Res; 2020 Feb; 81(1):3-22. PubMed ID: 31800139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of storage temperature and moisture on the performance of microsphere/hydrogel composites.
    Wang Y; Burgess DJ
    Int J Pharm; 2013 Sep; 454(1):310-5. PubMed ID: 23811131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deliquescence of pharmaceutical systems.
    Mauer LJ; Taylor LS
    Pharm Dev Technol; 2010 Dec; 15(6):582-94. PubMed ID: 19895256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of degradation of imidapril hydrochloride in finished dosage formulations.
    Stanisz B; Regulska K
    Acta Pol Pharm; 2013; 70(4):737-42. PubMed ID: 23923397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E
    Ann Pharm Fr; 2002 May; 60(3):161-76. PubMed ID: 12050595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding pharmaceutical polymorphic transformations II: crystallization variables and influence on dosage forms.
    Sood J; Sapra B; Bhandari S; Tiwary AK
    Ther Deliv; 2015; 6(6):721-40. PubMed ID: 26149787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Following the surface response of caffeine cocrystals to controlled humidity storage by atomic force microscopy.
    Cassidy AM; Gardner CE; Jones W
    Int J Pharm; 2009 Sep; 379(1):59-66. PubMed ID: 19539735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulation of tablets containing an 'in-process' amorphized active pharmaceutical ingredient.
    Jójárt-Laczkovich O; Szabó-Révész P
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1272-81. PubMed ID: 21457129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.